The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis-Reference-Cited by-同舟云学术

The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis

Published:2019 Issue:10 Volume:119 Page:100
ISSN:1997-7298
Container-title:Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova
language:en
Short-container-title:Z. nevrol. psikhiatr. im. S.S. Korsakova

Author:

Boyko A. N.,Bakhtiyarova K. Z.,Dudin V. A.,Zaslavsky L. G.,Malkova N. A.,Parshina Ye. V.,Fedulov A. S.,Zinkina-Orikhan A. V.,Linkova Yu. N.,Ivanov R. A.,Chernovskaya T. V.

Publisher

Media Sphere Publishing Group

Subject

Psychiatry and Mental health,Neurology (clinical)

Reference6 articles.

1. Interferon after 10 years in patients with multiple sclerosis

2. Salmon P, Le Cotonnec J-Y, Galazka A, Abdul-Ahad A, Darragh A. Pharmacokinetics and Pharmacodynamics of Recombinant Human Interferon-β in Healthy Male Volunteers. J Inreferon and Cytokine Research. 1996;16:759-764.

3. Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE

4. Baker DP, Lin EY, Lin K, Pellegrini M, Petter RC, Chen LL, Arduini RM, Brickelmaier M, Wen D, Hess DM, Chen L, Grant D, Whitty A, Gill A, Lindner DJ, Pepinsky RB. Nterminally PEGylated human interferon-beta-1a with improved pharmacokinetic properties and in vivo efficacy in a melanoma angiogenesis model. Bioconjug Chem. 2006;17:179-188.

5. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Russian-Belarusian Expert Council “New opportunities in the treatment of patients with multiple sclerosis” (October 1, 2023). Main conclusions of the first meeting;Neurology, Neuropsychiatry, Psychosomatics;2023-12-17

2. Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-11-30

3. The evolution of interferon therapy in multiple sclerosis;Neurology, Neuropsychiatry, Psychosomatics;2023-08-21

4. Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results;Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2023

5. Ways to improve adherence to long-term injection therapy in multiple sclerosis using the example of pegylated interferon-β1a (sampeginterferon β-1a);Neurology, Neuropsychiatry, Psychosomatics;2022-08-04